Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

NCT06126263 · clinicaltrials.gov ↗

UNKNOWN

Status

1000

Enrollment

NIH

Sponsor class

Conditions

Streptococcal Sepsis
Invasive Group A Beta-Haemolytic Streptococcal Disease
Necrotizing Soft Tissue Infection
Infection, Bloodstream
Infection, Bacterial
Streptococcal Toxic Shock Syndrome

Interventions

DRUG: Linezolid
DRUG: Clindamycin

Sponsor

National Institutes of Health Clinical Center (CC)

Collaborators

[object Object]